image
Healthcare - Biotechnology - NASDAQ - US
$ 0.0381
-15.1 %
$ 199 K
Market Cap
-0.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VINC stock under the worst case scenario is HIDDEN Compared to the current market price of 0.0381 USD, Vincerx Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VINC stock under the base case scenario is HIDDEN Compared to the current market price of 0.0381 USD, Vincerx Pharma, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VINC stock under the best case scenario is HIDDEN Compared to the current market price of 0.0381 USD, Vincerx Pharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VINC

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5$0.0$0.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-31.5 M OPERATING INCOME
26.16%
-30.1 M NET INCOME
25.11%
-26.1 M OPERATING CASH FLOW
35.41%
212 K INVESTING CASH FLOW
-99.49%
18 M FINANCING CASH FLOW
15682.46%
0 REVENUE
0.00%
-3.33 M OPERATING INCOME
62.23%
-5 M NET INCOME
37.45%
-4.45 M OPERATING CASH FLOW
27.94%
0 INVESTING CASH FLOW
0.00%
3.86 M FINANCING CASH FLOW
291.47%
Balance Sheet Vincerx Pharma, Inc.
image
Current Assets 6.41 M
Cash & Short-Term Investments 4.99 M
Receivables 1.04 M
Other Current Assets 382 K
Non-Current Assets 1.6 M
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 1.6 M
62.30 %13.00 %4.77 %19.93 %Total Assets$8.0m
Current Liabilities 5.28 M
Accounts Payable 2.03 M
Short-Term Debt 0
Other Current Liabilities 3.25 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
38.42 %61.58 %Total Liabilities$5.3m
EFFICIENCY
Earnings Waterfall Vincerx Pharma, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 31.5 M
Operating Income -31.5 M
Other Expenses -1.39 M
Net Income -30.1 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)000(31m)(31m)1m(30m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-1104.04% ROE
-1104.04%
-375.69% ROA
-375.69%
-1155.03% ROIC
-1155.03%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vincerx Pharma, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)202020202021202120222022202320232024202420252025
Net Income -30.1 M
Depreciation & Amortization 1.09 M
Capital Expenditures 0
Stock-Based Compensation 3.47 M
Change in Working Capital -178 K
Others -148 K
Free Cash Flow -26.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vincerx Pharma, Inc.
image
Wall Street analysts predict an average 1-year price target for VINC of $2 , with forecasts ranging from a low of $2 to a high of $2 .
VINC Lowest Price Target Wall Street Target
2 USD 5149.34%
VINC Average Price Target Wall Street Target
2 USD 5149.34%
VINC Highest Price Target Wall Street Target
2 USD 5149.34%
Price
Max Price Target
Min Price Target
Average Price Target
181816161414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Vincerx Pharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders globenewswire.com - 2 weeks ago
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 globenewswire.com - 2 months ago
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. globenewswire.com - 2 months ago
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx. globenewswire.com - 3 months ago
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated. globenewswire.com - 4 months ago
Vincerx Pharma, Inc. Announces Reverse Stock Split Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 globenewswire.com - 5 months ago
VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma, Inc. (NasdaqCM: VINC) and Oqory, Inc. Pursuant to the terms of the agreement, at the closing of the transaction, Vincerx equity holders will hold about 5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger. businesswire.com - 6 months ago
VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Upon completion of the proposed transaction, Vincerx equity holders will hold about 5% of the combined company. Halper Sadeh encourages Vincerx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade. businesswire.com - 6 months ago
Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Oqory merge with Vincerx and Oqory equity holders will own approximately 95% of the combined en. businesswire.com - 6 months ago
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline globenewswire.com - 6 months ago
Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943 Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts globenewswire.com - 7 months ago
What Makes Vincerx Pharma (VINC) a New Buy Stock Vincerx Pharma (VINC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 8 months ago
8. Profile Summary

Vincerx Pharma, Inc. VINC

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 199 K
Dividend Yield 0.00%
Description Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Contact 260 Sheridan Avenue, Palo Alto, CA, 94306 https://vincerx.com
IPO Date May 27, 2020
Employees 12
Officers Mr. Tom C. Thomas J.D. Consultant Dr. Ahmed M. Hamdy M.D. Co-Founder & Chairman Ms. Melissa Merrick SPHR Senior Director of People & Culture and Head of Human Resource Dr. John C. Byrd M.D. Founder & Chairman of Scientific Advisory Board Dr. Raquel E. Izumi Ph.D. Co-Founder, Acting Chief Executive Officer, Secretary & Director Mr. Alexander A. Seelenberger M.B.A. Consultant Ms. Gabriela Jairala Vice President of Investor Relations & Corporate Communications and Chief of Staff Mr. Kevin Haas Acting Chief Financial Officer, Vice President of Finance & Corporate Controller Ms. Karen Quarford M.B.A. Vice President of Quality Operations & Compliance Dr. Hans-Georg Lerchen Ph.D. Chief Scientific Officer